Rationale: Neovascularization is required for embryonic development and plays a central role in diseases in adults. In atherosclerosis, the role of neovascularization remains to be elucidated. In a genome-wide microarrayscreen of Flk1؉ angioblasts during murine embryogenesis, the v-ets erythroblastosis virus E26 oncogene homolog 2 (Ets2) transcription factor was identified as a potential angiogenic factor.
A therosclerosis is a complex disease with a strong inflammatory component, [1] [2] [3] [4] initially triggered by endothelial dysfunction and characterized by an influx of atherogenic lipoprotein components, combined with endothelial upregulation of proinflammatory cytokines and adhesion molecules. 5 Monocyte adhesion and extravasation perpetuate the disease by further differentiation into macrophages and foam cells, ultimately driving atherosclerotic lesion growth and complexity. 6 Vulnerable plaque (VP) is an advanced form of atherosclerosis, characterized by an exuberated inflammatory response with the formation of a large necrotic core, and a rupture-prone thin fibrous cap. 7 In these VPs, microvessel formation with extravasation of erythrocytes in the vasa vasorum and intimal area has been observed. 8 -10 Although new vessel formation in advanced atherosclerosis has been associated with lesion progression and instability, 10 -12 the exact molecular mechanisms that facilitate neovascularization in atherosclerosis must be further elucidated.
Recently, we have conducted a genome-wide screen to identify new genetic regulators of angiogenesis. The v-ets erythroblastosis virus E26 oncogene homolog 2 (Ets2) transcription factor was shown to be upregulated during murine embryonic angiogenesis in Flk1ϩ angioblasts. Expression of Ets2 in the vascular bed was also verified in developing zebra fish by whole mount in situ hybridization. Ets2 belongs to a family of transcription factors that share the E26 Transformation-specific Sequence (Ets) domain that recognizes a specific core sequence (5Ј-GGAA/T-3Ј). This functional domain is conserved in differ-ent species. 13 Ets2 has been shown to be a potent transactivator of angiogenic regulators, including vascular endothelial cell growth factor receptor (VEGFR)1, 14 heme oxygenase 1 (HO-1), 15 and cluster of differentiation 13 (CD13)/APN. 16 Ets2 was also studied in immune activation and was shown to be involved in the transcriptional regulation of cytokines including interleukin (IL)5 17 and IL12p40, 18 suggesting a prominent role in immune response regulation.
We postulated that Ets2 could mediate immune-activation of the endothelium in the late phase of atherosclerosis development, as well as promoting monocyte adhesion via neovessel activation. In addition, Ets2 might be an important modulator in microvessel formation of the vasa vasorum in atherosclerotic lesions and thus contribute to plaque destabilization in advanced lesions. We show that Ets2 induces atherosclerotic plaque destabilization by promoting an endothelial cell (EC) phenotype of enhanced inflammatory state.
Methods

Analysis of Human Atherosclerotic Plaques in Human Carotid Endarterectomy Specimens
Atherosclerosis samples were obtained from a biobank collection of endarterectomy-derived specimens of patients who had been diagnosed with symptomatic carotid artery disease (Athero Express Biobank, University Medical Center Utrecht, The Netherlands). The study was approved by an institutional review committee, and all the subjects involved provided informed consent. Samples had been processed for immunohistological analysis, as well as protein extraction, and were quantified by 2 independent observers for histomorphological indices of plaque vulnerability, as reported earlier. 19 
Vulnerable Plaque Model in Apolipoprotein E ؊/؊ Mice
All experiments were conducted in compliance with institutional (Erasmus University Medical Center, Rotterdam, The Netherlands) and national guidelines. apolipoprotein (Apo)E Ϫ/Ϫ mice (12 to 25 weeks; Jackson Laboratory, Bar Harbor, ME) on a Western-type diet (diet W, Hope Farms, The Netherlands) were anesthetized by isoflurane inhalation and received a cast implantation in the right common carotid artery position. At 6 weeks after cast placement, animals were anesthetized, and 50 L of 1ϫ10 10 pfu/mL recombinant adenovirus (either Ets2-Ad or ⌬E1-Ad, v/v 1:1) or lentivirus (either LV-siEts2 or LV-sisham, vol/vol 1:1) mixed with pluronic gel (Sigma, The Netherlands) was applied to the adventitia proximal to the cast, the predicted location of the vulnerable plaque. After an incubation time of 10 minutes, the gel was coagulated and the wound was closed; 21 days later, the carotid arteries were harvested for histological and immunohistochemical analysis.
Retina Transfection in ApoE ؊/؊ Mice
ApoE Ϫ/Ϫ mice (12 to 15 weeks; Jackson Laboratory, Bar Harbor, ME) were anesthetized by isoflurane inhalation and received intravitreal microinjection of 2 L of 0.5ϫ10 10 pfu/mL recombinant adenovirus (either Ets2-Ad or ⌬E1-Ad). Animals were allowed to recover and were euthanized 2 days after injections.
Tube Formation Assays
In vitro formation of tube structures was studied on BioCoat Matrigel tissue culture plates (BD Biosciences, Alphen a/d Rijn, The Netherlands). SiRNA-transfected HUVECs were plated at 30 000 cells/well in 96-well plates precoated with a solution of Matrigel basement membrane matrix. After 24 hours of incubation at 37°C, cells were visualized by Calcein-Am uptake (BD Biosciences). Tube organization was examined using an inverted fluorescence microscopy, and the photographs were subsequently analyzed using the commercial image analysis system (AngioSys, Buckingham, UK). Statistical analysis was performed using 1-way ANOVA. Data are presented as meanϮSEM; probability values Ͻ0.05 were considered significant.
Full protocol descriptions of the material and methods are provided in the Online supplemental data available online at http://circres.ahajournals.org.
Results
Ets2 Levels Correlate With Intraplaque Microvessel Formation and Levels of Proinflammatory Cytokines in Human Vulnerable Atherosclerotic Plaques
Ets2 protein levels were quantified by ELISA in carotid endarterectomy (CEA) specimens obtained from patients with documented symptomatic carotid artery disease. A full-length recombinant Ets2 protein was used as a positive control and for assay calibration. Patients were categorized into quartiles according to Ets2 levels (Online Table I Figure 1A ), but mean Ets2 levels do not differ between stable fibrous or vulnerable atheromatous plaque phenotype (Pϭ0.18; Figure 1B ). Ets2 protein levels specifically correlated with increased plaque thrombogenicity and erythrocyte extravasation in atheromatous plaques (PϽ0,05 versus Q2, Figure 1C ), the phenotypic characteristics of vulnerable plaque. In contrast, these correlations were absent in fibrous atherosclerotic lesions ( Figure 1D ). To further investigate the relation between Ets2 levels and inflammation in human atherosclerotic lesions, tumor necrosis factor-␣ (TNF␣), IL6, and monocyte chemoattractant protein 1 (MCP1) levels were assessed using commercial ELISAs. Ets2 protein levels showed correlations with TNF␣, IL6, and MCP1 levels (TNF␣: Rϭ0.31, Pϭ0.03; IL6: Rϭ0.31, Pϭ0.04; and MCP1: Rϭ0.40; Pϭ0.006; Figure 2A through 2C). In contrast, Ets2 showed an inverse correlation with VEGF-A protein levels (RϭϪ0.22; Pϭ0.05, Figure  2D ). Immunohistological analysis of serial sections shows specific expression of Ets2 in the neocapillaries of human advanced atherosclerotic plaques and in the endothelium covering the lesion ( Figure 2E ). Taken together, these findings point toward a possible regulatory role for Ets2 in angiogenesis, vascular integrity, and inflammatory state in vulnerable plaque.
Ets2 Expression Promotes Vulnerable Plaque Development in ApoE ؊/؊ Mice With Aggravated Vascularization and Intraplaque Hemorrhaging
The data obtained from the CEA human samples identified a potential function for Ets2 in regulating plaque neovascularization and inflammatory state. To further unravel Ets2 function in ECs in atherosclerosis, endogenous Ets2 protein expression was assessed in the endothelium of ApoE Ϫ/Ϫ mice. Whole-mount en face staining of major arteries of ApoE Ϫ/Ϫ mice, fed on normal chow, showed low Ets2 expression levels in the endothelium. However, Ets2 expression was markedly increased once ApoE Ϫ/Ϫ mice were placed on a high-fat high cholesterol diet (15% (wt/vol) cocoa butter and 0.25% (wt/vol) cholesterol; Figure 3A ). In addition, Ets2 mRNA levels were enhanced in murine advanced vulnerable lesions as compared with stable lesions or healthy contralateral vessels (PϽ0.05 stable and instable versus naive; †PϽ0,05 instable versus stable; Figure 3B ), as shown by quantitative polymerase chain reaction (qPCR) analysis, using a mouse model for vulnerable atherosclerotic plaque formation (VP model). 19 -21 Cross-sectional immunohistological analysis of murine VP validated the en face data as basal expression levels of Ets2 in carotid vessels derived from ApoE Ϫ/Ϫ animals on normal chow diet showed very weak Ets2 staining, which was mainly located outside the cell nuclei ( Figure 3C ). In contrast, Ets2 expression could be clearly detected in ECs in the murine VP lesions and colocalized with nuclear DAPI staining ( Figure 3D ). Ets2 expression was hardly detected in CD68ϩ macrophages that comprised the largest group of cells in the lesion ( Figure 3E ).
Ets2-specific staining was validated by immunostaining controls (Online Figure I , supplemental data). These findings suggest that Ets2-driven transcription is involved in atherosclerosis initiation and progression through the activated endothelium.
To assess in depth the function of Ets2 in advanced atherosclerosis specifically, Ets2 overexpression was induced in vessel segments with advanced atherosclerotic lesions in the earlier described murine VP model. Adenoviral transfection of Ets2 induced a 6-fold upregulation of Ets2 mRNA and 2-fold increase in Ets2 protein levels as compared with sham virus (⌬E1-Ad)-transfected animals, at 4 days after transfection (Online Figure II 
. Ets2 expression in human atherosclerotic lesions correlates with intraplaque neovascularization and increased thrombogenicity in human atheroma. A, Ets2 levels correlated with intraplaque neovascularization (Rϭ0.27;
Pϭ0.01) but was not upregulated in human atheromatous atherosclerotic lesions compared with fibrous plaques (B) (Pϭ0.12). C, Ets2 levels correlated with thrombogenicity in human atheromas (*PϽ0.05; versus Q2) but not in fibrous plaques (D). Values of plaque thrombogenicity were divided into 4 quartiles ranging form 0 (representing the group of patients with the lowest percentage) to 3 (representing the group of patients with the highest percentage) on the Y-axes. On the X-axes, Ets2 protein levels are shown, divided into 4 quartiles ranging from Q1 (representing the group of patients with the lowest percentage) to Q4 (representing the group of patients with the highest percentage).
Ets2 expression promoted intima/media ratio of VP lesions by ϩ130% as compared with ⌬E1-Ad virus-treated animals (PϽ0.05; Figure 4A ). In addition, Ets2 expression affected plaque phenotype: Lesions with Ets2 overexpression showed an increase in relative necrotic core size of ϩ141% (PϽ0.05; Figure 4B ). The relative fibrous cap thickness was decreased by Ϫ24% compared with the ⌬E1-Ad group (PϽ0,05; Figure 4C ). Ets2 expression in the atherosclerotic plaque region also increased intraplaque lipid accumulation by ϩ89% (*PϽ0.05; Figure 4D ) and CD68ϩ macrophage accumulation by ϩ46% (*PϽ0.05; Figure 4E ), compared with ⌬E1-Ad-transfected controls. Finally, Ets2 expression diminished VSMCs content by Ϫ41% (PϽ0.05; Figure 4F ), whereas collagen formation in the plaque remained unchanged compared with the ⌬E1-Ad group (Pϭ0.70; Figure 4G ), as analyzed using a circular polarization filter set.
To further validate the angiogenic function of Ets2 that was implied by the positive correlation between Ets2 levels and intraplaque capillary density in the CEA lesions, microvessel formation in the murine VP was assessed. Indeed, Ets2 increased microvessel formation in VP lesions by ϩ32% (PϽ0,05; Figure 5A ) as compared with control animals. To verify the role of Ets2 in intraplaque perivascular hemorrhaging (IPH), which was suggested by the human CEA study, the murine VP lesions were assessed for intimal accumulation of erythrocytes. Ets2-Ad-transfected ApoE Ϫ/Ϫ mice showed a significant increase in IPH, as detected by Ter119 erythrocyte immunostaining throughout the atherosclerotic lesions (PϽ0,05; Figure 5B ). The intraplaque Ter119 signal was mainly located outside the neovasculature of Ad-Ets2-treated murine lesions ( Figure 5C ). In addition, in line with the findings in human CEA, MCP1 and IL6 mRNA levels were upregulated in response to Ets2 expression in the carotid artery (Online Figure IV , supplemental data). These findings in the murine VP model demonstrate that Ets2 advances vulnerable plaque development. 
Regulation of Ets2 Expression and Angiogenic Function in Endothelial Cells by the Proatherogenic Cytokine TNF␣
To unravel the molecular mechanism by which Ets2 propagates neovascularization and IPH in advanced human and murine atheromatous lesions, we sought to define the decisive factors in atherosclerosis that are responsible for the rise in Ets2 expression in VP. Stimulation of HUVEC with different doses of LDL or oxLDL did not alter Ets2 expression levels (qPCR analysis, Figure 6A and 6B). No response was also observed in HUVEC cultures exposed to low oxygen conditions (21% versus 3% O 2 , Figure 6C ). However, stimulation of HUVECs with TNF␣, a proinflammatory cytokine associated with increased plaque vulnerability that correlated with Ets2 levels in human CEA study, induced a dose-dependent upregulation of Ets2 mRNA and protein levels ( Figure 6D and 6E). Simultaneously, TNF␣ stimulation of HUVECs induced Ets2 activation indicated by increase of Ets2 phosphorylation at Thr72 and visible nuclear translocation of this cotranscription factor ( Figure 6F and 6G) .
To validate the angiogenic potential of Ets2, in vitro tube formation experiments with HUVECs were conducted. Si- Further assessment of the transcriptional profile of Ets2 siRNA silencing in ECs indentified significant downregulation of proangiogenic genes, including HO-1, EphB4, EphrinB2, DLL4, Jagged1, and Ang-2, whereas the mRNA levels of Ang-1, VEGFA, and VEGFR2 remained unaffected ( Figure 6H ). These data point toward TNF␣ as a potent atherogenic factor that drives expression and proangiogenic function of Ets2 during intimal neovascularization.
Ets2 Drives Expression of the Proatherogenic Cytokines MCP1 and IL6 and the Adhesion Molecule VCAM1 in Endothelial Cells
The positive relation between Ets2 levels and the inflammatory cytokines TNF␣, IL6, and MCP1, as observed in human atherosclerotic lesions, could trigger monocyte adhesion to the luminal and adventitial microvascular endothelium, thereby promoting lesion growth and inflammatory state. We investigated the transcriptional regulation of Ets2 of the cytokines MCP1 and IL6, and the adhesion molecules VCAM1 and ICAM1 in HUVECs. SiRNA silencing of Ets2 impeded mRNA expression of MCP1, IL6 and VCAM1 expression, as compared with scrambled siRNA transfected cells (5 ng/1ϫ10 6 cells, 3 days after transfection, indicated by qPCR (PϽ0.05; Figure 7A through 7D). On TNF␣ coincubation, expression of MCP1, IL6, and VCAM1 was significantly increased. siRNA silencing of Ets2 abolished this effect, suggestive that Ets2 was involved in the transcriptional regulation of MCP1, IL6, and VCAM1 downstream of TNF␣ receptor interaction. ICAM1 levels remained unresponsive to Ets2 silencing under basal and TNF␣-stimulated conditions (PϽ0,05 Ets2; Figure 7A through 7D). In line with these findings, ELISA analysis showed that Ets2 silencing was associated with decreased protein levels of MCP1 and IL6 in the supernatant, as compared with sisham-transfected cells, either with or without TNF␣ stimulation ( Figure 7E and 7F) . These findings were validated in vivo, as Ets2 overexpression in murine carotid arteries induced the opposite effect and gave rise to increased mRNA levels of IL6 and MCP1 (qPCR analysis; Online Figure IV , supplemental data). Further qPCR analysis of the transfected cells showed that there was no cross-activation of the Ets1 target genes MMP1, MMP9, p21 CIP1 , and Ets1, validating the functional specificity of Ets2 (Online Figure IV, supplemental data) . These data point toward a role of Ets2 in regulating the inflammatory state of ECs that could define atherosclerotic lesion growth and promote further development into vulnerable plaque.
Ets2 Induces Loss of Integrity of Endothelial Monolayers in Response to TNF␣ In Vitro
To specify the mechanism by which Ets2 induced increased IPH, confluent endothelial monolayers of HUVECs transfected with ⌬E1-Ad and Ets2-Ad were cultured on nontransparent 0.4-m pore filters, followed by measurement of transwell endothelial leakage for 40-kDa dextran-FITC in the 
Figure 6. Ets2 responds to TNF␣ stimulation and promotes gene expression of angiogenic regulators in ECs. A, Endogenous
Ets2 mRNA levels in HUVECs were not responsive to different doses of LDL (range, 0 to 50 g/mL), or B, oxLDL (range, 0 to 50 g/mL) as assessed by qPCR at different time points. C, Similarly hypoxia failed to induce Ets2 expression (normal oxygen, 21% O 2 versus low oxygen 3% O 2 ). D, TNF␣ stimulation (range, 0 to 50 ng/mL) induced a dose-response in Ets2 mRNA expression (nϭ4; *PϽ0,05 versus 0 ng/mL TNF␣); E, total Ets2 protein levels (nϭ3; *PϽ0,05 versus 0 ng/mL TNF␣); and F, Ets2 phosphorylation at the lower chamber in the presence of either 25 ng/mL TNF␣ or 2 g/mL thrombin. Baseline levels of leakage of dextran-FITC remained low in unstimulated HUVECs both in Ets2-expressing cells and control cells. However, Ets2 expression significantly amplified the dextran-FITC signal by maximal 4-fold in response to TNF␣ ( Figure 7G ) or thrombin (data not shown), as compared with ⌬E1-Ad-infected cells, indicating that Ets2 augmented TNF␣ (and thrombin)-induced leakage of the endothelial monolayer. Loss of vascular integrity could be due to VE-cadherin shedding, a process mediated by ADAM10, a metallopeptidase prominent in the atherogenesis. ADAM10 mRNA levels assessment by qPCR revealed that Ets2 expression indeed induced a 2.5-fold upregulation of ADAM10, as compared with ⌬E1-Ad transfected HUVECs. Ets2 expression further amplified TNF␣-stimulated ADAM10 expression by 4-fold ( Figure 7H ). A similar effect was observed with thrombin stimulation (data not shown). These data identify Ets2 as an important regulator of endothelial leakage in response to proinflammatory stimuli.
Ets2 Overexpression Leads to Vascular Leakage and Leukocyte Infiltration In Vivo in the Retinal
Vasculature of ApoE ؊/؊ Mice
To further validate our findings of Ets2-induced hemorrhaging in the murine VP model, Ets2 overexpression was induced by intravitreal injection of Ets2-Ad in mature ApoE Ϫ/Ϫ mice, and the effect on vascular integrity was assessed 2 days after transfection. Ets2 overexpression in the murine retina induced severe hemorrhaging in response to intravenous thrombin injection, starting from the boundary areas closest to the lens, where the choroid and the retina layers begin to overlap, spreading further out to the anterior and vitreous eye chamber ( Figure 7I) . In contrast, the eyes injected with sham virus did not show any response. Dissection from the choroid layer and closer examination followed by quantification of the retina revealed large patches of thrombi in the eyes treated with Ets2-Ad as compared with sham-treated samples ( Figure 7J) . Similarly, we used this eye model to assess the effect of Ets2 overexpression on leukocyte adhesion to validate the role of Ets2 in immuneregulation. Whole-mount en face staining for CD45ϩ leukocytes revealed prominent leukocyte infiltration in Ets2-Ad treated eyes as compared with sham-treated controls ( Figure 7K) .
These findings in the murine retinal model demonstrate that Ets2 could compromise vessel integrity by promoting vascular leakage in response to inflammatory stimulation, thereby enhancing leukocyte adhesion.
ShRNA-Mediated Ets2 Silencing Stabilizes Vulnerable Plaque Morphology in ApoE ؊/؊ Mice
To validate the effects of Ets2 overexpression on VP phenotype, we conducted a second series of experiments in which we silenced endogenous Ets2 expression in the murine lesions. Ets2 silencing was induced in vessel segments with advanced atherosclerosis in the murine VP model by lentiviral transfection of an shRNA construct that targets Ets2. LV-siEts2 silencing induced a Ϫ50% downregulation of Ets2 mRNA levels as compared with vessels transfected by a control nontargeting shRNAlentiviral construct or nontransfected controls, at 4 days after transfection in murine carotid vessels ( Figure 8A ).
Ets2 silencing in murine VP impeded the intima/media ratio of these lesions by Ϫ55% and Ϫ50% as compared with LV-sisham or control animals, respectively ( Figure 8B ). Ets2 silencing also affected plaque phenotype: Lesions transfected with LV-siEts2 showed a decrease in relative necrotic core size of Ϫ83% versus LV-sisham and control animals ( Figure  8C ). The relative fibrous cap thickness was increased by ϩ64% and ϩ87% as compared with LV-sisham and control animals, respectively ( Figure 8D ).
Ets2 silencing further stabilized these advanced lesions, indicated by a reduction in intimal CD68ϩ macrophage by Ϫ55% and Ϫ59% (as compared with LV-sisham or control animals, respectively), whereas lipid deposition was not affected ( Figure  8E and 8F) . In contrast, Ets2 silencing increased plaque stabilization by promoting intraplaque VSMC accumulation by ϩ194% and ϩ99% as compared with LV-sisham and control, respectively, whereas collagen levels remained comparable to the controls (Figure 8G and 8H) .
Furthermore, Ets2 silencing decreased microvessel formation in VP lesions by Ϫ88% and Ϫ79%, which coincided with a decline in intraplaque Ter119 area of Ϫ76% and Ϫ73% as compared with LV-sisham or control animals ( Figure 8I and 8J ).
Discussion
The current study provides evidence for a central role for Ets2 in the development of a proatherogenic endothelial cell phenotype by stimulating expression of inflammatory cytokines that could subsequently contribute to intraplaque microvessel formation with concomitant loss of vascular integrity.
The initial clinical study of human CEA identified Ets2 as a potential biomarker for the extent of neovascularization and intraplaque hemorrhaging in advanced human atheromas. This coincided with a correlation between rising intraplaque levels of Ets2 and atherogenic inflammatory markers, including TNF␣, IL6, and MCP1. Based on the role of Ets2 as a potent transcriptional regulator of inflammatory cytokines, 17, 18 and the observation that Ets2 is upregulated in the Flk1ϩ angioblasts during vascular development in mice and zebra fish, we hypothesized that Ets2 could have a proatherogenic function in advanced atherosclerotic plaque development.
Our data demonstrated that Ets2 is upregulated in the vascular endothelium of ApoE Ϫ/Ϫ animals in response to a high cholesterol diet. In addition, Ets2 mRNA levels were in particular upregulated in the endothelium of murine vulnerable lesions, as compared with the endothelium of healthy vessels or stable atherosclerotic lesions. In vitro experiments to pinpoint the proatherogenic stimulus for Ets2 upregulation in advanced lesions identified TNF␣ as a potent factor that enhanced mRNA and protein levels of Ets2 in primary human ECs in culture.
Although the Ets2 correlation data in human atheromas gave an indication that Ets2 might be involved in VP formation, it did not demonstrated in a cause-effective way that Ets2 function could directly affect disease development.
To fully understand the role of Ets2 in VP pathogenesis, we conducted in vivo experiments in which we induced Ets2 overexpression in a murine VP model. Ets2 overexpression promoted lesion growth and induced progression of advanced lesions into a VP phenotype. This was marked by an increase of necrotic core and macrophage-covered area, a decrease in fibrous cap thickness, and a loss of VSMC content. More importantly, the formation of leaky microvessels formation was promoted, as identified by an increase in microvessels and hemorrhaging in the atherosclerotic area. In contrast, Ets2 silencing induced the opposite effect and was shown to stabilize the murine VP lesions. Together, these data point toward a destabilizing function for Ets2 in the advanced lesions.
Further experiments were conducted to unravel the working mechanism of Ets2 in ECs during VP progression. Based on our findings, we propose the following mechanism by which Ets2 in ECs could affect the stability of atherosclerotic lesions: In early advanced lesions, the proinflammatory cytokine (TNF␣)-rich environment triggers Ets2 expression. Ets2 functions as a modulator and amplifier of the endothelial inflammatory response via transcriptional activation of IL6, MCP1, and VCAM1, which promotes accumulation of inflammatory cells and thus heighten the inflammatory state of the atherosclerotic lesion. As suggested by our in vitro findings, Ets2 could potentially promote further lesion destabilization by directly effecting EC function, promoting vessel leakage and expansive neovascular growth from the adventitia into the intimal area, which supplies a second entry route for inflammatory cells. However, the observed effect of Ets2 on plaque stability could also predominantly be the result of the increased inflammatory state of the vulnerable lesion, which would also affect neovessel growth and IPH.
Ets2 has been shown to be involved in the transcriptional activation of angiogenic growth factors, including HO-1, 15 VEGFR1, 14 and CD13/APN. 16 In the present study, we further examined the angiogenic potential of Ets2 in vitro and in vivo. Our findings suggested that Ets2 promoted microvessel formation in the atherosclerotic region and caused subsequent plaque destabilization. Previously, animal studies have indicated that angiogenic factors, including VEGFA and placental growth factor could, in addition to regulate angiogenesis during organ development, also promote atherosclerosis formation, 22, 23 whereas inhibitors of angiogenesis (angiostatin, VEGF receptorblocking antibodies) were capable in reducing plaque growth. 24, 25 In addition, several studies have linked the formation of complex adventitial and intimal vascular networks to VP development. 8 -10,26 In line with these findings, enhanced microvessel formation by Ets2 overexpression in the plaque region of our murine VP model was observed, whereas a significant reduction in microangiogenesis was observed in Ets2 silenced lesions. In vitro, Ets2 regulated tube formation in HUVECs and was essential in regulating the expression of HO-1, a potent proangiogenic factor. 27, 28 Ets2 silencing also inhibited expression of EphrinB2, EphB4, Jagged1, and DLL4. Both DLL4/Jagged1/notch1/4 and EphrinB2/EphB4 signaling are vital regulatory pathways for angiogenesis. 29, 30 In addition, Ets2 silencing downregulated Ang-2 expression, whereas Ang-1 expression remained unaffected. Previous studies have shown that Ang-2 acts as a potent autocrine antagonist of Ang-1 activation of the Tie2 receptor. Tie2 signaling mediates endothelial cell survival and vessel stabilization. Blocking of the Tie2 pathway by Ang-2 creates an endothelium that is more susceptible for vascular destabilization during an inflammatory response and promotes tumor angiogenesis. 31 Combined, these findings imply that the proangiogenic function of Ets2 might be attributed to direct regulation of these proangiogenic pathways at the level of gene transcription by Ets2.
Ets2 correlated with pathological criteria of plaque vulnerability in the murine VP model but failed to show a clear correlation in human vulnerable plaque. However, recent clinical studies have suggested that independent predictors for plaque rupture and major adverse cardiac events are intraplaque microvessel growth and intraplaque hemorrhaging (reviewed in Reference 10). 10 In this perspective, Ets2 levels in human atheroma did show a correlation with both intraplaque microvessel density and thrombogenicity, suggestive of a plaque-destabilizing role for Ets2 in the murine and human vulnerable plaques that could be attributed to inflammation-driven neovascularization in the lesions. In addition, whereas in the mouse VP study the atherosclerotic lesions were assessed at 9 weeks during early onset of vulnerable plaque, the clinical study included patients with a heterogeneous history of cardiovascular disease in which the age of atheromatous or fibrous lesions remained difficult to determine by immunohistological and morphological assessment. Ets2 expression in VP could therefore be timedependent, and could be mainly an early determinant of plaque vulnerability, whereas Ets2 correlations with plaque vulnerability become less clear in the complex group of advanced lesions with more pleiotropic manifestations of vulnerable plaque, including postrupture lesions with a VSMC/collagen rich healed thrombus that compose the new fibrous cap, nonruptured calcified lesions, and lesions with xanthomas or advanced lesions overlaying the cap. 7 More importantly, intraplaque microvessels often lack endothelial integrity, 8 which results in vascular leakage and perivascular accumulation of erythrocyte-derived free cholesterol in the necrotic core. The ensuing increase in macrophage infiltration and foam cell formation could propagate progression from stable into vulnerable lesion. 6,8 -10,32,33 We show that Ets2 could promote loss of vascular endothelial integrity in response to TNF␣ stimulation, whereas Ets2 overexpression in the VP region increased intraplaque hemorrhaging. Several inflammatory mediators, including TNF␣, indeed could increase vascular leakage by upregulation of the metallopeptidase ADAM10 that could induce gaps in the adherens junctions by active proteolysis of VE-cadherin. 34 However, the potential role of Ets2 in vascular growth and vessel leakage during vulnerable plaque progression should still be interpreted with discretion: Advanced atherosclerotic lesion progression is a complex, multifaceted disease, and Ets2 function, as discussed earlier, could also be primarily dependent on the regulation of Ets2 in cytokine and adhesion factor expression in ECs. Although our murine in vivo model provides unique opportunities to study the effect of Ets2 on vulnerable plaque stability, it remains difficult to separate the effects of inflammation, neovascularization and vascular integrity regulation as each of these mechanisms are so heavily intertwined in the natural process of the disease. In addition, considering the relative weak correlations that were observed between Ets2 levels and the different inflammation and lesion morphological markers of plaque vulnerability in the human samples, extrapolation of the findings in vitro and the murine model to the human disease should be discreet.
Conclusion
The current study provides first evidence for the plaquedestabilizing role of Ets2 in atherosclerosis development. Ets2 enhances the TNF␣-driven inflammatory response of the endothelium, leading to a proatherosclerotic environment that promotes inflammatory infiltration and subsequent microvessel formation with compromised vascular integrity in the VP region that ultimately affects lesion stability.
